215 related articles for article (PubMed ID: 15715969)
1. Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase.
Shank RP; Doose DR; Streeter AJ; Bialer M
Epilepsy Res; 2005 Feb; 63(2-3):103-12. PubMed ID: 15715969
[TBL] [Abstract][Full Text] [Related]
2. Topiramate as an inhibitor of carbonic anhydrase isoenzymes.
Dodgson SJ; Shank RP; Maryanoff BE
Epilepsia; 2000; 41(S1):35-9. PubMed ID: 10768298
[TBL] [Abstract][Full Text] [Related]
3. Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers.
Clark AM; Kriel RL; Leppik IE; Marino SE; Mishra U; Brundage RC; Cloyd JC
Epilepsia; 2013 Jun; 54(6):1099-105. PubMed ID: 23506041
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.
Britzi M; Perucca E; Soback S; Levy RH; Fattore C; Crema F; Gatti G; Doose DR; Maryanoff BE; Bialer M
Epilepsia; 2005 Mar; 46(3):378-84. PubMed ID: 15730535
[TBL] [Abstract][Full Text] [Related]
5. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate.
Lambrecht LJ; Shekh-Ahmad T; Todd WM; Halvorsen MB; Bialer M
Epilepsia; 2011 Oct; 52(10):1877-83. PubMed ID: 21770925
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic monitoring of topiramate: evaluation of the saturable distribution between erythrocytes and plasma of whole blood using an optimized high-pressure liquid chromatography method.
Gidal BE; Lensmeyer GL
Ther Drug Monit; 1999 Oct; 21(5):567-76. PubMed ID: 10519457
[TBL] [Abstract][Full Text] [Related]
8. Topiramate pharmacokinetics in infants.
Glauser TA; Miles MV; Tang P; Clark P; McGee K; Doose DR
Epilepsia; 1999 Jun; 40(6):788-91. PubMed ID: 10368080
[TBL] [Abstract][Full Text] [Related]
9. Topiramate modulates pH of hippocampal CA3 neurons by combined effects on carbonic anhydrase and Cl-/HCO3- exchange.
Leniger T; Thöne J; Wiemann M
Br J Pharmacol; 2004 Jul; 142(5):831-42. PubMed ID: 15197104
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling.
Jovanović M; Sokić D; Grabnar I; Vovk T; Prostran M; Vučićević K; Miljković B
Eur J Pharm Sci; 2013 Nov; 50(3-4):282-9. PubMed ID: 23891703
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioavailability of topiramate in the beagle dog.
Streeter AJ; Stahle PL; Holland ML; Pritchard JF; Takacs AR
Drug Metab Dispos; 1995 Jan; 23(1):90-3. PubMed ID: 7720530
[TBL] [Abstract][Full Text] [Related]
12. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years.
Mikaeloff Y; Rey E; Soufflet C; d'Athis P; Echenne B; Vallée L; Bouhours P; Grinspan A; Dulac O; Pons G; Chiron C
Epilepsia; 2004 Nov; 45(11):1448-52. PubMed ID: 15509246
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.
Mimrod D; Specchio LM; Britzi M; Perucca E; Specchio N; La Neve A; Soback S; Levy RH; Gatti G; Doose DR; Maryanoff BE; Bialer M
Epilepsia; 2005 Jul; 46(7):1046-54. PubMed ID: 16026556
[TBL] [Abstract][Full Text] [Related]
14. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
15. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients.
Doose DR; Brodie MJ; Wilson EA; Chadwick D; Oxbury J; Berry DJ; Schwabe S; Bialer M
Epilepsia; 2003 Jul; 44(7):917-22. PubMed ID: 12823574
[TBL] [Abstract][Full Text] [Related]
16. The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate.
Gidal BE; Clark AM; Anders B; Gilliam F
Epilepsy Res; 2017 Jan; 129():26-32. PubMed ID: 27883934
[TBL] [Abstract][Full Text] [Related]
17. Effect of pregnancy on topiramate pharmacokinetics in rabbits.
Matar KM; Marafie NA
Xenobiotica; 2011 May; 41(5):416-21. PubMed ID: 21271806
[TBL] [Abstract][Full Text] [Related]
18. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response.
Ferrari AR; Guerrini R; Gatti G; Alessandrì MG; Bonanni P; Perucca E
Ther Drug Monit; 2003 Dec; 25(6):700-8. PubMed ID: 14639056
[TBL] [Abstract][Full Text] [Related]
19. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate.
Clark AM; Kriel RL; Leppik IE; White JR; Henry TR; Brundage RC; Cloyd JC
Epilepsia; 2013 Jun; 54(6):1106-11. PubMed ID: 23586686
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects.
Nunes T; Sicard E; Almeida L; Falcão A; Rocha JF; Brunet JS; Lefebvre M; Soares-da-Silva P
Curr Med Res Opin; 2010 Jun; 26(6):1355-62. PubMed ID: 20377319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
